ES2992063T3 - Compuestos y procedimientos de uso de los mismos - Google Patents
Compuestos y procedimientos de uso de los mismos Download PDFInfo
- Publication number
- ES2992063T3 ES2992063T3 ES17874657T ES17874657T ES2992063T3 ES 2992063 T3 ES2992063 T3 ES 2992063T3 ES 17874657 T ES17874657 T ES 17874657T ES 17874657 T ES17874657 T ES 17874657T ES 2992063 T3 ES2992063 T3 ES 2992063T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- heteroaryl
- heterocyclyl
- carbocyclyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 title claims description 87
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 80
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 37
- 206010015037 epilepsy Diseases 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 201000007547 Dravet syndrome Diseases 0.000 claims abstract description 9
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims abstract description 9
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims abstract description 9
- 108010052164 Sodium Channels Proteins 0.000 claims abstract description 8
- 102000018674 Sodium Channels Human genes 0.000 claims abstract description 8
- 230000002159 abnormal effect Effects 0.000 claims abstract description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 6
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 6
- 239000011734 sodium Substances 0.000 claims abstract description 6
- 230000001594 aberrant effect Effects 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 125
- 125000000623 heterocyclic group Chemical group 0.000 claims description 117
- 125000003118 aryl group Chemical group 0.000 claims description 85
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 78
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 58
- 125000005843 halogen group Chemical group 0.000 claims description 56
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 56
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 50
- -1 hydrocarbon group radical Chemical class 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 33
- 125000003342 alkenyl group Chemical group 0.000 claims description 32
- 125000000304 alkynyl group Chemical group 0.000 claims description 32
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- 208000014644 Brain disease Diseases 0.000 claims description 23
- 208000032274 Encephalopathy Diseases 0.000 claims description 23
- 230000001037 epileptic effect Effects 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 7
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 230000008901 benefit Effects 0.000 claims description 5
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims 50
- 125000004432 carbon atom Chemical group C* 0.000 claims 49
- 206010010904 Convulsion Diseases 0.000 claims 27
- 230000035772 mutation Effects 0.000 claims 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 16
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 15
- 239000001301 oxygen Chemical group 0.000 claims 15
- 208000002877 Epileptic Syndromes Diseases 0.000 claims 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 14
- 239000011593 sulfur Chemical group 0.000 claims 14
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 10
- 125000004122 cyclic group Chemical group 0.000 claims 10
- 208000024658 Epilepsy syndrome Diseases 0.000 claims 9
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 9
- 206010061334 Partial seizures Diseases 0.000 claims 9
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims 8
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 claims 8
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 claims 8
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims 8
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 claims 8
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 claims 8
- 208000023944 Sudden Unexpected Death in Epilepsy Diseases 0.000 claims 8
- 150000003254 radicals Chemical class 0.000 claims 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 7
- 208000011580 syndromic disease Diseases 0.000 claims 7
- 206010003805 Autism Diseases 0.000 claims 6
- 208000020706 Autistic disease Diseases 0.000 claims 6
- 241000282414 Homo sapiens Species 0.000 claims 6
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 claims 6
- 206010021750 Infantile Spasms Diseases 0.000 claims 6
- 208000000060 Migraine with aura Diseases 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 claims 6
- 201000006791 West syndrome Diseases 0.000 claims 6
- 206010067039 familial hemiplegic migraine Diseases 0.000 claims 6
- 201000007186 focal epilepsy Diseases 0.000 claims 6
- 208000018360 neuromuscular disease Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 6
- 101000944018 Homo sapiens Potassium channel subfamily T member 1 Proteins 0.000 claims 5
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims 5
- 102100033508 Potassium channel subfamily T member 1 Human genes 0.000 claims 5
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 210000004556 brain Anatomy 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- 208000009575 Angelman syndrome Diseases 0.000 claims 4
- 102100022554 E3 ubiquitin-protein ligase NHLRC1 Human genes 0.000 claims 4
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 claims 4
- 208000002091 Febrile Seizures Diseases 0.000 claims 4
- 101000973111 Homo sapiens E3 ubiquitin-protein ligase NHLRC1 Proteins 0.000 claims 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 claims 4
- 208000028326 generalized seizure Diseases 0.000 claims 4
- 230000000155 isotopic effect Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 3
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims 3
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 claims 3
- 208000020749 Benign familial neonatal-infantile seizures Diseases 0.000 claims 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 3
- 208000006561 Cluster Headache Diseases 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 3
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 claims 3
- 208000001914 Fragile X syndrome Diseases 0.000 claims 3
- 208000003078 Generalized Epilepsy Diseases 0.000 claims 3
- 208000027109 Headache disease Diseases 0.000 claims 3
- 206010019476 Hemiplegic migraine Diseases 0.000 claims 3
- 101001072243 Homo sapiens Protocadherin-19 Proteins 0.000 claims 3
- 101000693993 Homo sapiens Sodium channel protein type 4 subunit alpha Proteins 0.000 claims 3
- 208000007599 Hyperkalemic periodic paralysis Diseases 0.000 claims 3
- 208000009612 Laryngismus Diseases 0.000 claims 3
- 206010023891 Laryngospasm Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 208000033180 Monosomy 22q13.3 Diseases 0.000 claims 3
- 206010061533 Myotonia Diseases 0.000 claims 3
- 208000012905 Myotonic disease Diseases 0.000 claims 3
- 208000037158 Partial Epilepsies Diseases 0.000 claims 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 3
- 102100036389 Protocadherin-19 Human genes 0.000 claims 3
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims 3
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims 3
- 208000006289 Rett Syndrome Diseases 0.000 claims 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 3
- 201000007410 Smith-Lemli-Opitz syndrome Diseases 0.000 claims 3
- 102100027195 Sodium channel protein type 4 subunit alpha Human genes 0.000 claims 3
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 208000032212 benign familial infantile 3 seizures Diseases 0.000 claims 3
- 229910052796 boron Inorganic materials 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000002566 clonic effect Effects 0.000 claims 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 206010014599 encephalitis Diseases 0.000 claims 3
- 201000002933 epilepsy with generalized tonic-clonic seizures Diseases 0.000 claims 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 201000005706 hypokalemic periodic paralysis Diseases 0.000 claims 3
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 230000001617 migratory effect Effects 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 208000027838 paramyotonia congenita of Von Eulenburg Diseases 0.000 claims 3
- 208000029308 periodic paralysis Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 239000011574 phosphorus Chemical group 0.000 claims 3
- 208000000415 potassium-aggravated myotonia Diseases 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 229910052710 silicon Chemical group 0.000 claims 3
- 239000010703 silicon Chemical group 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 230000001256 tonic effect Effects 0.000 claims 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 3
- 208000009999 tuberous sclerosis Diseases 0.000 claims 3
- 201000000866 velocardiofacial syndrome Diseases 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 claims 2
- 102100030390 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Human genes 0.000 claims 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 102100024005 Acid ceramidase Human genes 0.000 claims 2
- 102100024085 Alpha-aminoadipic semialdehyde dehydrogenase Human genes 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 102100028215 BTB/POZ domain-containing protein KCTD7 Human genes 0.000 claims 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 2
- 102100029962 CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Human genes 0.000 claims 2
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 claims 2
- 102100026793 Carboxypeptidase A6 Human genes 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 claims 2
- 102100040499 Contactin-associated protein-like 2 Human genes 0.000 claims 2
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 claims 2
- 102100026891 Cystatin-B Human genes 0.000 claims 2
- 101000923091 Danio rerio Aristaless-related homeobox protein Proteins 0.000 claims 2
- 102100021236 Dynamin-1 Human genes 0.000 claims 2
- 102100029108 Elongation factor 1-alpha 2 Human genes 0.000 claims 2
- 101710150822 G protein-regulated inducer of neurite outgrowth 1 Proteins 0.000 claims 2
- 102000017696 GABRA1 Human genes 0.000 claims 2
- 102000017707 GABRB3 Human genes 0.000 claims 2
- 102000017703 GABRG2 Human genes 0.000 claims 2
- 102100022688 GATOR complex protein DEPDC5 Human genes 0.000 claims 2
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 claims 2
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 claims 2
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 claims 2
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 claims 2
- 102100024013 Golgi SNAP receptor complex member 2 Human genes 0.000 claims 2
- 102100025296 Guanine nucleotide-binding protein G(o) subunit alpha Human genes 0.000 claims 2
- 102100031470 Homeobox protein ARX Human genes 0.000 claims 2
- 101000583063 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Proteins 0.000 claims 2
- 101000975753 Homo sapiens Acid ceramidase Proteins 0.000 claims 2
- 101000690235 Homo sapiens Alpha-aminoadipic semialdehyde dehydrogenase Proteins 0.000 claims 2
- 101001007222 Homo sapiens BTB/POZ domain-containing protein KCTD7 Proteins 0.000 claims 2
- 101000863898 Homo sapiens CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Proteins 0.000 claims 2
- 101001049859 Homo sapiens Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 claims 2
- 101000910782 Homo sapiens Carboxypeptidase A6 Proteins 0.000 claims 2
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 claims 2
- 101000749877 Homo sapiens Contactin-associated protein-like 2 Proteins 0.000 claims 2
- 101000945692 Homo sapiens Cyclin-dependent kinase-like 5 Proteins 0.000 claims 2
- 101000912191 Homo sapiens Cystatin-B Proteins 0.000 claims 2
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 claims 2
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 claims 2
- 101000817604 Homo sapiens Dynamin-1 Proteins 0.000 claims 2
- 101000841231 Homo sapiens Elongation factor 1-alpha 2 Proteins 0.000 claims 2
- 101001044724 Homo sapiens GATOR complex protein DEPDC5 Proteins 0.000 claims 2
- 101000893331 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-1 Proteins 0.000 claims 2
- 101001073597 Homo sapiens Gamma-aminobutyric acid receptor subunit beta-3 Proteins 0.000 claims 2
- 101000926813 Homo sapiens Gamma-aminobutyric acid receptor subunit gamma-2 Proteins 0.000 claims 2
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 claims 2
- 101000972850 Homo sapiens Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 claims 2
- 101000904234 Homo sapiens Golgi SNAP receptor complex member 2 Proteins 0.000 claims 2
- 101000857837 Homo sapiens Guanine nucleotide-binding protein G(o) subunit alpha Proteins 0.000 claims 2
- 101000923090 Homo sapiens Homeobox protein ARX Proteins 0.000 claims 2
- 101000994012 Homo sapiens Immediate early response 3-interacting protein 1 Proteins 0.000 claims 2
- 101000834851 Homo sapiens KICSTOR complex protein SZT2 Proteins 0.000 claims 2
- 101000652814 Homo sapiens Lactosylceramide alpha-2,3-sialyltransferase Proteins 0.000 claims 2
- 101000876418 Homo sapiens Laforin Proteins 0.000 claims 2
- 101000882389 Homo sapiens Laforin, isoform 9 Proteins 0.000 claims 2
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 claims 2
- 101000782865 Homo sapiens Neuronal acetylcholine receptor subunit alpha-2 Proteins 0.000 claims 2
- 101000745167 Homo sapiens Neuronal acetylcholine receptor subunit alpha-4 Proteins 0.000 claims 2
- 101000726901 Homo sapiens Neuronal acetylcholine receptor subunit beta-2 Proteins 0.000 claims 2
- 101001094809 Homo sapiens Polynucleotide 5'-hydroxyl-kinase Proteins 0.000 claims 2
- 101000994632 Homo sapiens Potassium voltage-gated channel subfamily A member 2 Proteins 0.000 claims 2
- 101000997292 Homo sapiens Potassium voltage-gated channel subfamily B member 1 Proteins 0.000 claims 2
- 101000997283 Homo sapiens Potassium voltage-gated channel subfamily C member 1 Proteins 0.000 claims 2
- 101001009074 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Proteins 0.000 claims 2
- 101000742002 Homo sapiens Prickle-like protein 1 Proteins 0.000 claims 2
- 101000742006 Homo sapiens Prickle-like protein 2 Proteins 0.000 claims 2
- 101000577696 Homo sapiens Proline-rich transmembrane protein 2 Proteins 0.000 claims 2
- 101000710213 Homo sapiens Protein CLN8 Proteins 0.000 claims 2
- 101000797874 Homo sapiens Putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13 Proteins 0.000 claims 2
- 101001066905 Homo sapiens Pyridoxine-5'-phosphate oxidase Proteins 0.000 claims 2
- 101000641879 Homo sapiens Ras/Rap GTPase-activating protein SynGAP Proteins 0.000 claims 2
- 101000927773 Homo sapiens Rho guanine nucleotide exchange factor 9 Proteins 0.000 claims 2
- 101000709238 Homo sapiens Serine/threonine-protein kinase SIK1 Proteins 0.000 claims 2
- 101000702707 Homo sapiens Smad nuclear-interacting protein 1 Proteins 0.000 claims 2
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 claims 2
- 101000684813 Homo sapiens Sodium channel subunit beta-1 Proteins 0.000 claims 2
- 101000704203 Homo sapiens Spectrin alpha chain, non-erythrocytic 1 Proteins 0.000 claims 2
- 101000629629 Homo sapiens Sushi repeat-containing protein SRPX2 Proteins 0.000 claims 2
- 101000821100 Homo sapiens Synapsin-1 Proteins 0.000 claims 2
- 101000585079 Homo sapiens Syntaxin-1B Proteins 0.000 claims 2
- 101000648077 Homo sapiens Syntaxin-binding protein 1 Proteins 0.000 claims 2
- 101000788505 Homo sapiens TBC1 domain family member 24 Proteins 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 102100031531 Immediate early response 3-interacting protein 1 Human genes 0.000 claims 2
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 claims 2
- 102100026895 KICSTOR complex protein SZT2 Human genes 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- 102100030928 Lactosylceramide alpha-2,3-sialyltransferase Human genes 0.000 claims 2
- 102100038889 Laforin, isoform 9 Human genes 0.000 claims 2
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 claims 2
- 102100020983 Lysosome membrane protein 2 Human genes 0.000 claims 2
- 108010018650 MEF2 Transcription Factors Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 102100040273 Mitochondrial glutamate carrier 1 Human genes 0.000 claims 2
- 102100039229 Myocyte-specific enhancer factor 2C Human genes 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- 102100035585 Neuronal acetylcholine receptor subunit alpha-2 Human genes 0.000 claims 2
- 102100039909 Neuronal acetylcholine receptor subunit alpha-4 Human genes 0.000 claims 2
- 102100030912 Neuronal acetylcholine receptor subunit beta-2 Human genes 0.000 claims 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical class [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 102100035460 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 claims 2
- 102100034369 Potassium voltage-gated channel subfamily A member 2 Human genes 0.000 claims 2
- 102100034310 Potassium voltage-gated channel subfamily B member 1 Human genes 0.000 claims 2
- 102100034308 Potassium voltage-gated channel subfamily C member 1 Human genes 0.000 claims 2
- 102100034360 Potassium voltage-gated channel subfamily KQT member 3 Human genes 0.000 claims 2
- 102100027376 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Human genes 0.000 claims 2
- 102100038630 Prickle-like protein 1 Human genes 0.000 claims 2
- 102100038629 Prickle-like protein 2 Human genes 0.000 claims 2
- 102100028840 Proline-rich transmembrane protein 2 Human genes 0.000 claims 2
- 102100034479 Protein CLN8 Human genes 0.000 claims 2
- 102100032337 Putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13 Human genes 0.000 claims 2
- 102100034407 Pyridoxine-5'-phosphate oxidase Human genes 0.000 claims 2
- 102100033428 Ras/Rap GTPase-activating protein SynGAP Human genes 0.000 claims 2
- 102000043322 Reelin Human genes 0.000 claims 2
- 108700038365 Reelin Proteins 0.000 claims 2
- 101150057388 Reln gene Proteins 0.000 claims 2
- 102100033221 Rho guanine nucleotide exchange factor 9 Human genes 0.000 claims 2
- 108091005488 SCARB2 Proteins 0.000 claims 2
- 108091006587 SLC13A5 Proteins 0.000 claims 2
- 108091006426 SLC25A22 Proteins 0.000 claims 2
- 108091006296 SLC2A1 Proteins 0.000 claims 2
- 108091006539 SLC35A2 Proteins 0.000 claims 2
- 102000005028 SLC6A1 Human genes 0.000 claims 2
- 108060007759 SLC6A1 Proteins 0.000 claims 2
- 102100032771 Serine/threonine-protein kinase SIK1 Human genes 0.000 claims 2
- 102100030914 Smad nuclear-interacting protein 1 Human genes 0.000 claims 2
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 claims 2
- 102100023732 Sodium channel subunit beta-1 Human genes 0.000 claims 2
- 102100035210 Solute carrier family 13 member 5 Human genes 0.000 claims 2
- 102100031874 Spectrin alpha chain, non-erythrocytic 1 Human genes 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 102100026826 Sushi repeat-containing protein SRPX2 Human genes 0.000 claims 2
- 102100021905 Synapsin-1 Human genes 0.000 claims 2
- 102100029931 Syntaxin-1B Human genes 0.000 claims 2
- 102100025293 Syntaxin-binding protein 1 Human genes 0.000 claims 2
- 102100025233 TBC1 domain family member 24 Human genes 0.000 claims 2
- 102100033782 UDP-galactose translocator Human genes 0.000 claims 2
- 108010036639 WW Domain-Containing Oxidoreductase Proteins 0.000 claims 2
- 102000012163 WW Domain-Containing Oxidoreductase Human genes 0.000 claims 2
- 208000028311 absence seizure Diseases 0.000 claims 2
- 230000009471 action Effects 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 2
- 150000001340 alkali metals Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims 2
- 208000008233 autosomal dominant nocturnal frontal lobe epilepsy Diseases 0.000 claims 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 229940077388 benzenesulfonate Drugs 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 claims 2
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims 2
- 229940043264 dodecyl sulfate Drugs 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 208000028316 focal seizure Diseases 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 150000007522 mineralic acids Chemical class 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 235000005985 organic acids Nutrition 0.000 claims 2
- UCDPMNSCCRBWIC-UHFFFAOYSA-N orthosulfamuron Chemical compound COC1=CC(OC)=NC(NC(=O)NS(=O)(=O)NC=2C(=CC=CC=2)C(=O)N(C)C)=N1 UCDPMNSCCRBWIC-UHFFFAOYSA-N 0.000 claims 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- GBROPGWFBFCKAG-UHFFFAOYSA-N picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- 230000009466 transformation Effects 0.000 claims 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 claims 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 claims 1
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000006017 1-propenyl group Chemical group 0.000 claims 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 claims 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 claims 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 206010052075 Acquired epileptic aphasia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims 1
- 206010003628 Atonic seizures Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical class [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical class CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical class CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010053398 Clonic convulsion Diseases 0.000 claims 1
- 208000033001 Complex partial seizures Diseases 0.000 claims 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- 101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 claims 1
- 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical class [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- 201000009010 Frontal lobe epilepsy Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- 208000034308 Grand mal convulsion Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical class [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 206010034759 Petit mal epilepsy Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 201000001068 Prinzmetal angina Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 101150058068 SLC2A1 gene Proteins 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 206010042434 Sudden death Diseases 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims 1
- 206010043994 Tonic convulsion Diseases 0.000 claims 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 208000003443 Unconsciousness Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 claims 1
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 claims 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 claims 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 claims 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical class [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229920000615 alginic acid Chemical class 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 150000001342 alkaline earth metals Chemical class 0.000 claims 1
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Chemical class OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 125000005228 aryl sulfonate group Chemical group 0.000 claims 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Chemical class 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 125000002785 azepinyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 229940050390 benzoate Drugs 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000005978 brain dysfunction Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical class [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 150000001722 carbon compounds Chemical class 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229910052729 chemical element Inorganic materials 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 claims 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 claims 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 claims 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 claims 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 230000003205 diastolic effect Effects 0.000 claims 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 claims 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 claims 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 125000005879 dioxolanyl group Chemical group 0.000 claims 1
- 125000005883 dithianyl group Chemical group 0.000 claims 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical class CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 206010016284 febrile convulsion Diseases 0.000 claims 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 229940050410 gluconate Drugs 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- QSQIGGCOCHABAP-UHFFFAOYSA-N hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical class CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 claims 1
- 125000006038 hexenyl group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005980 hexynyl group Chemical group 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 239000005414 inactive ingredient Substances 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 238000005342 ion exchange Methods 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 229940001447 lactate Drugs 0.000 claims 1
- 229940099584 lactobionate Drugs 0.000 claims 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims 1
- 229940070765 laurate Drugs 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002151 myoclonic effect Effects 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical class C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 claims 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Chemical class 0.000 claims 1
- 230000000422 nocturnal effect Effects 0.000 claims 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 1
- PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 claims 1
- WTFQBTLMPISHTA-UHFFFAOYSA-N octaphene Chemical compound C1=CC=C2C=C(C=C3C4=CC5=CC6=CC7=CC=CC=C7C=C6C=C5C=C4C=CC3=C3)C3=CC2=C1 WTFQBTLMPISHTA-UHFFFAOYSA-N 0.000 claims 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 claims 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- LSQODMMMSXHVCN-UHFFFAOYSA-N ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 claims 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 235000006408 oxalic acid Nutrition 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003551 oxepanyl group Chemical group 0.000 claims 1
- 125000003585 oxepinyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000000466 oxiranyl group Chemical group 0.000 claims 1
- NRZWYNLTFLDQQX-UHFFFAOYSA-N p-tert-Amylphenol Chemical compound CCC(C)(C)C1=CC=C(O)C=C1 NRZWYNLTFLDQQX-UHFFFAOYSA-N 0.000 claims 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 claims 1
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 claims 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 claims 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 125000005981 pentynyl group Chemical group 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 claims 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 claims 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 229940075930 picrate Drugs 0.000 claims 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229950010765 pivalate Drugs 0.000 claims 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 1
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 230000001020 rhythmical effect Effects 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 claims 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical class OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 208000005809 status epilepticus Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000005458 thianyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001583 thiepanyl group Chemical group 0.000 claims 1
- 125000003777 thiepinyl group Chemical group 0.000 claims 1
- 125000002053 thietanyl group Chemical group 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 238000000844 transformation Methods 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000005881 triazolinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
- 125000005580 triphenylene group Chemical group 0.000 claims 1
- 229910052722 tritium Inorganic materials 0.000 claims 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims 1
- 229940070710 valerate Drugs 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 abstract description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 7
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 4
- 229910001415 sodium ion Inorganic materials 0.000 description 4
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical group F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 3
- 108010081348 HRT1 protein Hairy Chemical group 0.000 description 3
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical group [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427044P | 2016-11-28 | 2016-11-28 | |
| US201762458306P | 2017-02-13 | 2017-02-13 | |
| US201762552073P | 2017-08-30 | 2017-08-30 | |
| PCT/US2017/063533 WO2018098499A1 (en) | 2016-11-28 | 2017-11-28 | Compounds and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2992063T3 true ES2992063T3 (es) | 2024-12-09 |
Family
ID=62195384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17874657T Active ES2992063T3 (es) | 2016-11-28 | 2017-11-28 | Compuestos y procedimientos de uso de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11629146B2 (https=) |
| EP (2) | EP4397308A3 (https=) |
| JP (4) | JP7105797B2 (https=) |
| CN (2) | CN110337295B (https=) |
| AU (3) | AU2017364901A1 (https=) |
| BR (1) | BR112019010880A2 (https=) |
| CA (2) | CA3281817A1 (https=) |
| DK (1) | DK3548033T3 (https=) |
| ES (1) | ES2992063T3 (https=) |
| FI (1) | FI3548033T3 (https=) |
| HU (1) | HUE068842T2 (https=) |
| PL (1) | PL3548033T3 (https=) |
| PT (1) | PT3548033T (https=) |
| WO (1) | WO2018098499A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| WO2019232209A1 (en) * | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| BR112021003224A2 (pt) | 2018-08-20 | 2021-07-20 | Rogcon, Inc. | oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| WO2021039961A1 (ja) * | 2019-08-30 | 2021-03-04 | 大日本住友製薬株式会社 | 縮環ピラゾール誘導体 |
| EP4065124A4 (en) * | 2019-11-26 | 2023-12-06 | Praxis Precision Medicines, Inc. | ION CHANNEL MODULATORS |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| US12552797B2 (en) * | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| AU2022343895A1 (en) * | 2021-09-13 | 2024-03-28 | Boehringer Ingelheim Vetmedica Gmbh | Cyclopropyl-(hetero)aryl-substituted ethylsulphonylpyridine derivatives |
| MX2024013240A (es) | 2022-04-26 | 2024-12-06 | Praxis Prec Medicines Inc | Tratamiento de trastornos neurologicos |
| EP4598927A2 (en) * | 2022-10-07 | 2025-08-13 | Tenvie Therapeutics Inc. | Compounds, compositions, and methods |
| CN119613413B (zh) * | 2024-12-26 | 2026-02-06 | 上海皓元医药股份有限公司 | 一种非唑奈坦的制备方法 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4230705A (en) * | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| CA1080712A (en) * | 1976-09-22 | 1980-07-01 | Jay D. Albright | Hypotensive agents |
| US4112095A (en) * | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
| US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| GB9507348D0 (en) | 1995-04-08 | 1995-05-31 | Knoll Ag | Therapeutic agents |
| WO2002006286A2 (en) | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| MXPA05012850A (es) * | 2003-05-29 | 2006-05-17 | New River Pharmaceuticals Inc | Compuestos de anfetamina resistentes al abuso. |
| AU2005212096B2 (en) | 2004-02-18 | 2010-12-16 | Msd K.K. | Nitrogenous fused heteroaromatic ring derivative |
| WO2006061428A2 (en) * | 2004-12-10 | 2006-06-15 | Universität Zürich | Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
| US20100088778A1 (en) | 2005-06-16 | 2010-04-08 | John Charles Mulley | Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene |
| HUE030390T2 (en) | 2005-12-21 | 2017-05-29 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| CA2713521A1 (en) | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| US20100125091A1 (en) | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds as ion channel modulators |
| JP5657566B2 (ja) | 2008-12-24 | 2015-01-21 | バイアル ポルテラ アンド シーエイ エス エイＢＩＡＬ−Ｐｏｒｔｅｌａ ＆ Ｃａ， Ｓ．Ａ． | 医薬品 |
| JP5340798B2 (ja) | 2009-05-07 | 2013-11-13 | タイガースポリマー株式会社 | 地中埋設管の製造方法 |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| US8952034B2 (en) * | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2011056985A2 (en) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
| FR2953520B1 (fr) | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| WO2012065297A1 (en) | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| US9139576B2 (en) | 2011-05-03 | 2015-09-22 | Merck Sharp & Dohme Corp. | Aminomethyl biaryl benzotriazole derivatives |
| CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| CA2849505A1 (en) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| US9586963B2 (en) | 2011-09-27 | 2017-03-07 | Genfit | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists |
| CN103122000B (zh) | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| TWI574962B (zh) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| US20140329755A1 (en) | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Combination therapy for the treatment of arrhythmias or heart failure |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| DK3035926T3 (da) | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| GB201321740D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| AU2014364783B2 (en) | 2013-12-19 | 2017-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| EP3152213B1 (en) * | 2014-06-04 | 2018-10-31 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| ES2912073T3 (es) | 2014-06-20 | 2022-05-24 | Mitsubishi Chem Corp | Policarbonatodiol, método para producir el mismo, y poliuretano producido usando el mismo |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| KR101819433B1 (ko) | 2014-06-26 | 2018-01-16 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체 |
| JP2017001991A (ja) | 2015-06-11 | 2017-01-05 | 大日本住友製薬株式会社 | 新規ベンズオキサゾロン化合物 |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| US20210188839A1 (en) | 2016-11-28 | 2021-06-24 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| WO2019232209A1 (en) | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| EP4065124A4 (en) | 2019-11-26 | 2023-12-06 | Praxis Precision Medicines, Inc. | ION CHANNEL MODULATORS |
| US12552797B2 (en) | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
-
2017
- 2017-11-28 DK DK17874657.4T patent/DK3548033T3/da active
- 2017-11-28 EP EP24160394.3A patent/EP4397308A3/en active Pending
- 2017-11-28 FI FIEP17874657.4T patent/FI3548033T3/fi active
- 2017-11-28 US US16/464,468 patent/US11629146B2/en active Active
- 2017-11-28 CA CA3281817A patent/CA3281817A1/en active Pending
- 2017-11-28 PT PT178746574T patent/PT3548033T/pt unknown
- 2017-11-28 CN CN201780084790.8A patent/CN110337295B/zh active Active
- 2017-11-28 EP EP17874657.4A patent/EP3548033B1/en active Active
- 2017-11-28 CN CN202310582446.9A patent/CN116763791A/zh active Pending
- 2017-11-28 HU HUE17874657A patent/HUE068842T2/hu unknown
- 2017-11-28 PL PL17874657.4T patent/PL3548033T3/pl unknown
- 2017-11-28 WO PCT/US2017/063533 patent/WO2018098499A1/en not_active Ceased
- 2017-11-28 BR BR112019010880-7A patent/BR112019010880A2/pt not_active Application Discontinuation
- 2017-11-28 CA CA3045121A patent/CA3045121C/en active Active
- 2017-11-28 ES ES17874657T patent/ES2992063T3/es active Active
- 2017-11-28 AU AU2017364901A patent/AU2017364901A1/en not_active Abandoned
- 2017-11-28 JP JP2019548536A patent/JP7105797B2/ja active Active
-
2022
- 2022-07-12 JP JP2022111844A patent/JP7495962B2/ja active Active
-
2023
- 2023-03-10 US US18/119,963 patent/US20230322790A1/en not_active Abandoned
- 2023-12-14 AU AU2023282271A patent/AU2023282271A1/en not_active Abandoned
-
2024
- 2024-05-24 JP JP2024084718A patent/JP7801794B2/ja active Active
- 2024-12-06 US US18/971,281 patent/US20250163068A1/en active Pending
-
2025
- 2025-09-23 AU AU2025237912A patent/AU2025237912A1/en active Pending
- 2025-12-23 JP JP2025279047A patent/JP2026062794A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116763791A (zh) | 2023-09-19 |
| JP7801794B2 (ja) | 2026-01-19 |
| JP2019535838A (ja) | 2019-12-12 |
| EP4397308A2 (en) | 2024-07-10 |
| DK3548033T3 (da) | 2024-07-15 |
| PL3548033T3 (pl) | 2025-06-02 |
| EP4397308A3 (en) | 2024-08-21 |
| WO2018098499A1 (en) | 2018-05-31 |
| AU2017364901A1 (en) | 2019-06-13 |
| JP2024100974A (ja) | 2024-07-26 |
| JP2022141773A (ja) | 2022-09-29 |
| JP7495962B2 (ja) | 2024-06-05 |
| US11629146B2 (en) | 2023-04-18 |
| PT3548033T (pt) | 2024-08-09 |
| US20230322790A1 (en) | 2023-10-12 |
| EP3548033B1 (en) | 2024-04-10 |
| CA3281817A1 (en) | 2026-03-02 |
| CA3045121A1 (en) | 2018-05-31 |
| EP3548033A4 (en) | 2020-09-09 |
| US20250163068A1 (en) | 2025-05-22 |
| JP7105797B2 (ja) | 2022-07-25 |
| AU2025237912A1 (en) | 2025-10-16 |
| CN110337295B (zh) | 2023-06-09 |
| HUE068842T2 (hu) | 2025-01-28 |
| CA3045121C (en) | 2025-12-16 |
| AU2023282271A1 (en) | 2024-01-18 |
| US20210188852A1 (en) | 2021-06-24 |
| EP3548033A1 (en) | 2019-10-09 |
| FI3548033T3 (fi) | 2024-07-10 |
| JP2026062794A (ja) | 2026-04-10 |
| BR112019010880A2 (pt) | 2019-10-01 |
| CN110337295A (zh) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2992063T3 (es) | Compuestos y procedimientos de uso de los mismos | |
| AU2023286014B2 (en) | Oxysterols and methods of use thereof | |
| US11926646B2 (en) | C7 substituted oxysterols and methods of use thereof | |
| ES3035617T3 (en) | Oxysterols and methods of use thereof | |
| ES3036110T3 (en) | Oxysterols and methods of use thereof | |
| ES3042115T3 (en) | Neuroactive steroids and methods of use thereof | |
| WO2017087864A1 (en) | Compounds and methods of their use | |
| WO2020210116A1 (en) | Steroids with altered pharmacokinetic properties and methods of use thereof | |
| EP4329735B1 (en) | Kcnt1 inhibitors and methods of use | |
| WO2020210117A1 (en) | Steroids with altered pharmacokinetic properties and methods of use thereof | |
| CA3247233A1 (en) | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND THEIR METHODS OF USE | |
| AU2023245572A1 (en) | T-type calcium channel modulators comprising an azaspirononane core and methods of use thereof | |
| CA3029900C (en) | Oxysterols and methods of use thereof | |
| EP4504188A1 (en) | T-type calcium channel modulators comprising an azaspiroheptane core and methods of use thereof | |
| WO2023211850A1 (en) | Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use | |
| HK40057080A (en) | Neuroactive steroids, compositions, and uses thereof | |
| WO2020251870A1 (en) | Steroids with altered pharmacokinetic properties and methods of use thereof | |
| WO2020251869A1 (en) | Steroids with altered pharmacokinetic properties and methods of use thereof | |
| HK40004830B (en) | C7 substituted oxysterols and these compounds for use as nmda modulators | |
| HK40004830A (en) | C7 substituted oxysterols and these compounds for use as nmda modulators | |
| EA046723B1 (ru) | Соединения и способы их применения | |
| HK40006669B (en) | 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions | |
| HK40000512B (en) | C17, c20, and c21 substituted neuroactive steroids and their methods of use | |
| HK40000512A (en) | C17, c20, and c21 substituted neuroactive steroids and their methods of use |